{"brief_title": "A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease", "brief_summary": "The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.", "condition": ["Alzheimer's Disease"], "intervention_type": ["Drug"], "intervention_name": ["ABT-089"], "criteria": "INCLUSION CRITERIA: - Current diagnosis of probable Alzheimer's disease. - ADAS-cog score of at least 12 and MMSE score of 10 to 26. - Non-smoker - Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person. - Fluent in English. EXCLUSION CRITERIA: - Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks. - Has clinically significant or uncontrolled medical condition other than Alzheimer's disease. - Nursing home resident.", "gender": "All", "minimum_age": "50 Years", "maximum_age": "85 Years", "healthy_volunteers": "No", "mesh_term": ["Alzheimer Disease"], "id": "NCT00069849"}